The protein landscape of chronic lymphocytic leukemia

• Verfasst von: Meier-Abt, Fabienne [VerfasserIn]
• Verfasst von: Lu, Junyan [VerfasserIn]
• Verfasst von: Cannizzaro, Ester [VerfasserIn]
• Verfasst von: Pohly, Marcel F. [VerfasserIn]
• Verfasst von: Kummer, Sandra [VerfasserIn]
• Verfasst von: Pfammatter, Sibylle [VerfasserIn]
• Verfasst von: Kunz, Laura [VerfasserIn]
• Verfasst von: Collins, Ben C. [VerfasserIn]
• Verfasst von: Nadeu, Ferran [VerfasserIn]
• Verfasst von: Lee, Kwang Seok [VerfasserIn]
• Verfasst von: Xue, Peng [VerfasserIn]
• Verfasst von: Gwerder, Myriam [VerfasserIn]
• Verfasst von: Roiss, Michael [VerfasserIn]
• Verfasst von: Hüllein, Jennifer [VerfasserIn]
• Verfasst von: Scheinost, Sebastian [VerfasserIn]
• Verfasst von: Dietrich, Sascha [VerfasserIn]
• Verfasst von: Campo, Elías [VerfasserIn]
• Verfasst von: Huber, Wolfgang [VerfasserIn]
• Verfasst von: Aebersold, Rudolf [VerfasserIn]
• Verfasst von: Zenz, Thorsten [VerfasserIn]
• Titel: The protein landscape of chronic lymphocytic leukemia
• Verf.angabe: Fabienne Meier-Abt, Junyan Lu, Ester Cannizzaro, Marcel F. Pohly, Sandra Kummer, Sibylle Pfammatter, Laura Kunz, Ben C. Collins, Ferran Nadeu, Kwang Seok Lee, Peng Xue, Myriam Gwerder, Michael Roiss, Jennifer Hüllein, Sebastian Scheinost, Sascha Dietrich, Elias Campo, Wolfgang Huber, Ruedi Aebersold, Thorsten Zenz
• E-Jahr: 2021
• Jahr: December 16 2021
• Umfang: 12 S.
• Fussnoten: Gesehen am 09.08.2022
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2021
• Band/Heft Quelle: 138(2021), 24, Seite 2514-2525
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood.2020009741
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1813783047

Abstract

Many functional consequences of mutations on tumor phenotypes in chronic lymphocytic leukemia (CLL) are unknown. This may be in part due to a scarcity of information on the proteome of CLL. We profiled the proteome of 117 CLL patient samples with data-independent acquisition mass spectrometry and integrated the results with genomic, transcriptomic, ex vivo drug response, and clinical outcome data. We found trisomy 12, IGHV mutational status, mutated SF3B1, trisomy 19, del(17)(p13), del(11)(q22.3), mutated DDX3X and MED12 to influence protein expression (false discovery rate [FDR] = 5%). Trisomy 12 and IGHV status were the major determinants of protein expression variation in CLL as shown by principal-component analysis (1055 and 542 differentially expressed proteins, FDR = 5%). Gene set enrichment analyses of CLL with trisomy 12 implicated B-cell receptor (BCR)/phosphatidylinositol 3-kinase (PI3K)/AKT signaling as a tumor driver. These findings were supported by analyses of protein abundance buffering and protein complex formation, which identified limited protein abundance buffering and an upregulated protein complex involved in BCR, AKT, MAPK, and PI3K signaling in trisomy 12 CLL. A survey of proteins associated with trisomy 12/IGHV-independent drug response linked STAT2 protein expression with response to kinase inhibitors, including Bruton tyrosine kinase and mitogen-activated protein kinase kinase (MEK) inhibitors. STAT2 was upregulated in unmutated IGHV CLL and trisomy 12 CLL and required for chemokine/cytokine signaling (interferon response). This study highlights the importance of protein abundance data as a nonredundant layer of information in tumor biology and provides a protein expression reference map for CLL.